001065343 Stock Overview
Provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Edwards Lifesciences Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$65.79 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | 1.1 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -55.02% |
| 5 Year Change | 8.56% |
| Change since IPO | 153.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| 001065343 | CH Medical Equipment | CH Market | |
|---|---|---|---|
| 7D | 0% | -0.3% | 0.6% |
| 1Y | n/a | 3.3% | 10.2% |
Return vs Industry: Insufficient data to determine how 001065343 performed against the Swiss Medical Equipment industry.
Return vs Market: Insufficient data to determine how 001065343 performed against the Swiss Market.
Price Volatility
| 001065343 volatility | |
|---|---|
| 001065343 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 4.1% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in CH Market | 7.9% |
| 10% least volatile stocks in CH Market | 1.7% |
Stable Share Price: 001065343's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: Insufficient data to determine 001065343's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1958 | 19,800 | Bernard Zovighian | www.edwards.com |
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve.
Edwards Lifesciences Corporation Fundamentals Summary
| 001065343 fundamental statistics | |
|---|---|
| Market cap | CHF 39.61b |
| Earnings (TTM) | CHF 1.26b |
| Revenue (TTM) | CHF 4.89b |
31.5x
P/E Ratio8.1x
P/S RatioIs 001065343 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 001065343 income statement (TTM) | |
|---|---|
| Revenue | US$5.44b |
| Cost of Revenue | US$1.12b |
| Gross Profit | US$4.32b |
| Other Expenses | US$2.92b |
| Earnings | US$1.40b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.38 |
| Gross Margin | 79.46% |
| Net Profit Margin | 25.75% |
| Debt/Equity Ratio | 7.4% |
How did 001065343 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/21 13:26 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Edwards Lifesciences Corporation is covered by 67 analysts. 32 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Francis Mainwaring | Atlantic Equities LLP |
| David Rescott | Baird |
| Ishan Majumdar | Baptista Research |